Patents by Inventor Simon Nicholas Lennard

Simon Nicholas Lennard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES THAT BIND IL-18 AND METHODS OF INHIBITING IL-18 ACTIVITY
    Publication number: 20130101595
    Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
    Type: Application
    Filed: September 5, 2012
    Publication date: April 25, 2013
    Applicant: Abbott Laboratories
    Inventors: Tariq Ghayer, Richard W. Dixon, Michael Roguska, Michael White, Boris Labkovsky, Jochen Salfeld, Alexander Robert Duncan, Simon Mark Brocklehurst, John Mankovich, Celia Patricia Shorrock, Julia Elizabeth Thompson, Simon Nicholas Lennard
  • ANTIBODIES THAT BIND IL-18 AND METHODS OF INHIBITING IL-18 ACTIVITY
    Publication number: 20110008357
    Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
    Type: Application
    Filed: May 24, 2010
    Publication date: January 13, 2011
    Applicant: Abbott Laboratories
    Inventors: Tariq Ghayer, Richard W. Dixon, Michael Roguska, Michael White, Boris Labkovsky, Jochen Salfeld, Alexander Robert Duncan, Simon Mark Brocklehurst, John Mankovich, Celia Patricia Shorrock, Julia Elizabeth Thompson, Simon Nicholas Lennard
  • Antibodies that bind IL-18 and methods of inhibiting IL-18 activity
    Patent number: 7767207
    Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: August 3, 2010
    Assignee: Abbott Laboratories
    Inventors: Tariq Ghayer, Richard W. Dixon, Michael Roguska, Michael White, Boris Labkovsky, Jochen Salfeld, Alexander Robert Duncan, Simon Mark Brocklehurst, John Mankovich, Celia Patricia Shorrock, Julia Elizabeth Thompson, Simon Nicholas Lennard
  • ANTIBODIES THAT BIND IL-18 AND METHODS OF INHIBITING IL-18 ACTIVITY
    Publication number: 20100104563
    Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
    Type: Application
    Filed: February 9, 2001
    Publication date: April 29, 2010
    Inventors: Tariq Ghayer, Richard W. Dixon, Michael Roguska, Michael White, Boris Labkovsky, Jochen Salfeld, Alexander Robert Duncan, Simon Mark Brocklehurst, John Mankovich, Celia Patricia Shorrock, Julia Elizabeth Thompson, Simon Nicholas Lennard
  • Specific binding members for TGF?
    Patent number: 7151169
    Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralising activity for TGF?1 and are useful in treating conditions associated with excess TGF?1 activity, such as fibrosis, immune responses and tumor progression.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: December 19, 2006
    Assignee: Cambridge Antibody Technology Limited
    Inventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
  • Specific binding members for TGFbeta1
    Publication number: 20030091566
    Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10).
    Type: Application
    Filed: September 13, 2002
    Publication date: May 15, 2003
    Inventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
  • Specific binding members for TGFbeta1
    Publication number: 20030064069
    Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10).
    Type: Application
    Filed: September 13, 2002
    Publication date: April 3, 2003
    Inventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
  • Specific binding members for TGFbeta1
    Patent number: 6492497
    Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralizing activity for TGF&bgr;1 and are useful in treating conditions associated with excess TGF&bgr;1 activity, such as fibrosis, immune responses and tumor progression.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: December 10, 2002
    Assignee: Cambridge Antibody Technology Limited
    Inventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest